N8 Medical Announces its CeraShield™ Coating inhibits COVID-19 Virus Growth on Endotracheal Tubes
Health Canada Grants Emergency Use Authorization for N8 Medical CeraShield™ Endotracheal Tubes in Mechanically Ventilated COVID-19 Patients
Frost & Sullivan awards N8 Medical New Product Innovation Award for its Platform Medical Device Technology to Prevent Hospital-Acquired Infections
N8 Medical Appoints Infectious Diseases Expert, David S. Perlin, Ph.D., to Scientific Advisory Board
N8 Medical Announces NHLBI Grant to Develop Antimicrobial Pacemaker Envelope
CeraShield™ resorbable envelope targets prevention of bacterial and highly lethal fungal infections and reduction of surgical site infections of pacemaker implantations
Published Research Shows CSA-131’s Potent Efficacy against Global Health Threat
New Publication regarding Ceragenin CSA-131’s Potent Efficacy against fungal pathogen Candida auris, a New Serious Global Health Threat
N8 Medical Announces Compelling Publication Supporting Its Breakthrough CeraShield™ Endotracheal Tube
CeraShield™ Coating Prevents Bacterial and Fungal Colonization, and Reduces Endotoxin
FDA Grants N8 Medical Breakthrough Device Designation
FDA Grants N8 Medical’s Request for Breakthrough Device Designation for its CeraShield™ Endotracheal Tube
New Research Shows CSA-131 has Potent Antifungal Activity
A recent published study by Professor Robert Bucki and colleagues has shown that CSA-131 has broad spectrum antifungal activity and retains activity in various body fluids.
